AFP Test Used in Liver Cancer Screening
In recent years, the screening of alpha-fetoprotein (AFP) for liver cancer has attracted wides attention. AFP is a biomarker for liver cancer. It can help doctors detecting liver cancer earlier and improve treatment success rates by detecting levels of AFP in blood.
Liver cancer is a common malignant tumor that often strikes patients without obvious symptoms, leading to increased treatment difficulty and even endangering lives. Therefore, early detection of liver cancer is crucial for patient survival and treatment success.
AFP screening is a simple, fast, and non-invasive detection method that can detect AFP levels in a small amount of blood. If AFP levels are higher than the normal range, doctors will further conduct imaging tests to determine whether liver cancer is present. However, it is important to note that AFP is not the only biomarker for liver cancer, so relying solely on AFP screening cannot completely rule out the presence of liver cancer. Therefore, when conducting AFP screening, it is necessary to combine multiple means such as imaging tests and medical history for comprehensive analysis to diagnose liver cancer.
In summary, AFP screening is an important method for early screening of liver cancer, which is significant for improving the treatment effect and survival rate of liver cancer patients. The alpha fetoprotein testing project independently developed and produced by Xiamen Wiz Biotech Co., Ltd. adopts the high specificity double antibody sandwich reaction principle, and the test results can be obtained in 15 minutes.
Wizbiotech always takes "focus on diagnostic technology, improve the quality of life" as its purpose, focuses on technological innovation, and hopes to make more contribution in the field of POCT rapid diagnosis.
For further information, please contact WIZ’s sales team.
